Company Description
Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally.
The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.
Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood.
The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. has a strategic collaboration with ANT Neuro to expand the capabilities of the NeuroStar advanced therapy system with advanced image-guided navigation technology.
The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
| Country | United States |
| Founded | 2003 |
| IPO Date | Jun 28, 2018 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 658 |
| CEO | Daniel Reuvers |
Contact Details
Address: 3222 Phoenixville Pike Malvern, Pennsylvania 19355 United States | |
| Phone | 877 600 7555 |
| Website | neurostar.com |
Stock Details
| Ticker Symbol | STIM |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001227636 |
| CUSIP Number | 64131A105 |
| ISIN Number | US64131A1051 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Daniel L. Reuvers | Chief Executive Officer, President and Director |
| W. Andrew Macan J.D. | EVice President, Chief Legal Officer and Corporate Secretary |
| Jeffrey S. Jones | Senior Vice President and Chief of Operations |
| Cory S. Anderson | SVice President and Chief Technology Officer |
| Lisa Metzner-Rosas | Senior Vice President and Chief Marketing Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 29, 2026 | SD | Form - SD |
| May 29, 2026 | 8-K | Current Report |
| May 27, 2026 | SCHEDULE 13D/A | Filing |
| May 22, 2026 | 8-K | Current Report |
| May 5, 2026 | 10-Q | Quarterly Report |
| May 5, 2026 | 8-K | Current Report |
| Apr 10, 2026 | EFFECT | Notice of Effectiveness |
| Apr 9, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 9, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 8, 2026 | SCHEDULE 13D/A | Filing |